Loading…

The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension

Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip...

Full description

Saved in:
Bibliographic Details
Published in:Basic & clinical pharmacology & toxicology 2015-10, Vol.117 (4), p.234-241
Main Authors: Cau, Stefany B. A., Guimaraes, Danielle A., Rizzi, Elen, Ceron, Carla S., Gerlach, Raquel F., Tanus‐Santos, Jose E.
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 241
container_issue 4
container_start_page 234
container_title Basic & clinical pharmacology & toxicology
container_volume 117
creator Cau, Stefany B. A.
Guimaraes, Danielle A.
Rizzi, Elen
Ceron, Carla S.
Gerlach, Raquel F.
Tanus‐Santos, Jose E.
description Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip (2K1C) hypertension‐induced left ventricular remodelling. Sham‐operated controls or 2K1C rats with hypertension received either vehicle or PDTC (100 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure was monitored every week. Histological assessment of left ventricles was carried out with haematoxylin/eosin sections, and fibrosis was quantified in picrosirius red‐stained sections. Oxidative stress was evaluated in heart samples with the dihydroethidium probe. Cardiac MMP activity was determined by in situ zymography, and cardiac MMP‐2 was assessed by immunofluorescence. 2K1C surgery significantly increased systolic blood pressure in the 2K1C vehicle. PDTC exerted antihypertensive effects after 2 weeks of treatment. Histology revealed increased left ventricular and septum wall thickness associated with augmented myocyte diameter in hypertensive rats, which were reversed by treatment with PDTC. Hypertensive rats developed pronounced cardiac fibrosis with increased interstitial collagen area, increased cardiac reactive oxygen species levels, gelatinase activity and MMP‐2 expression. PDTC treatment decreased these alterations. These findings show that PDTC modulates myocardial MMP‐2 expression and ameliorates cardiac remodelling in renovascular hypertension. These results suggest that interfering with MMP expression at transcriptional level may be an interesting strategy in the therapy of organ damage associated with hypertension.
doi_str_mv 10.1111/bcpt.12400
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1709466623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3797558641</sourcerecordid><originalsourceid>FETCH-LOGICAL-p3510-5d6e52178cad699686aa26a60e671315a1d823218ad733e9d28fb4bceddefae43</originalsourceid><addsrcrecordid>eNo9Uc1OGzEQtioqAimXPkBliXPAP7vezbGEApGSNkLhvJpdTxJTx956vZTceIQ-Rx-LJ6kDlLnM6Jtvfj9CPnN2xpOd100bz7jIGPtAjniRiVFRZvLgPZb5gBx33T1josg4OyQDkZdcFTw_In-XG6Tf-8YiBHoFTfSB_oS2hQs6dRtTmz2w2IXgrdHGIb00cWN8A6GGLUSki4AP6GJHJxC0gYbe4tZrtNa4NQWn6RxiMI90jhGs9W3wEY2DDp-f_gh61yZ3i-veQjTeUeNSvfMP0DUJCvRm12KI6LqU_EQ-rsB2ePLmh-Tu6ttycjOa_bieTr7ORq3MORvlWmEueFE2oNV4rEoFIBQohuliyXPguhRS8BJ0ISWOtShXdVY3qDWuADM5JKevfdOuv3rsYnXv--DSyIoXbJwppYRMrC9vrL7eoq7aYLYQdtX_1yYCfyX8NhZ373nOqr1o1V606kW06mKyWL5E8h8MCo-2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709466623</pqid></control><display><type>article</type><title>The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension</title><source>Wiley</source><creator>Cau, Stefany B. A. ; Guimaraes, Danielle A. ; Rizzi, Elen ; Ceron, Carla S. ; Gerlach, Raquel F. ; Tanus‐Santos, Jose E.</creator><creatorcontrib>Cau, Stefany B. A. ; Guimaraes, Danielle A. ; Rizzi, Elen ; Ceron, Carla S. ; Gerlach, Raquel F. ; Tanus‐Santos, Jose E.</creatorcontrib><description>Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip (2K1C) hypertension‐induced left ventricular remodelling. Sham‐operated controls or 2K1C rats with hypertension received either vehicle or PDTC (100 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure was monitored every week. Histological assessment of left ventricles was carried out with haematoxylin/eosin sections, and fibrosis was quantified in picrosirius red‐stained sections. Oxidative stress was evaluated in heart samples with the dihydroethidium probe. Cardiac MMP activity was determined by in situ zymography, and cardiac MMP‐2 was assessed by immunofluorescence. 2K1C surgery significantly increased systolic blood pressure in the 2K1C vehicle. PDTC exerted antihypertensive effects after 2 weeks of treatment. Histology revealed increased left ventricular and septum wall thickness associated with augmented myocyte diameter in hypertensive rats, which were reversed by treatment with PDTC. Hypertensive rats developed pronounced cardiac fibrosis with increased interstitial collagen area, increased cardiac reactive oxygen species levels, gelatinase activity and MMP‐2 expression. PDTC treatment decreased these alterations. These findings show that PDTC modulates myocardial MMP‐2 expression and ameliorates cardiac remodelling in renovascular hypertension. These results suggest that interfering with MMP expression at transcriptional level may be an interesting strategy in the therapy of organ damage associated with hypertension.</description><identifier>ISSN: 1742-7835</identifier><identifier>EISSN: 1742-7843</identifier><identifier>DOI: 10.1111/bcpt.12400</identifier><identifier>PMID: 25816715</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Animals ; Blood Pressure ; Collagen - metabolism ; Disease Models, Animal ; Fibrosis ; Heart Ventricles - drug effects ; Heart Ventricles - enzymology ; Heart Ventricles - pathology ; Heart Ventricles - physiopathology ; Hypertension, Renovascular - complications ; Hypertension, Renovascular - drug therapy ; Hypertension, Renovascular - enzymology ; Hypertension, Renovascular - pathology ; Hypertension, Renovascular - physiopathology ; Hypertrophy, Left Ventricular - enzymology ; Hypertrophy, Left Ventricular - etiology ; Hypertrophy, Left Ventricular - pathology ; Hypertrophy, Left Ventricular - physiopathology ; Hypertrophy, Left Ventricular - prevention &amp; control ; Male ; Matrix Metalloproteinase 2 - metabolism ; NF-kappa B - antagonists &amp; inhibitors ; NF-kappa B - metabolism ; Oxidative Stress - drug effects ; Pyrrolidines - pharmacology ; Rats, Wistar ; Thiocarbamates - pharmacology ; Time Factors ; Up-Regulation ; Ventricular Function, Left - drug effects ; Ventricular Remodeling - drug effects</subject><ispartof>Basic &amp; clinical pharmacology &amp; toxicology, 2015-10, Vol.117 (4), p.234-241</ispartof><rights>2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)</rights><rights>2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).</rights><rights>Copyright © 2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25816715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cau, Stefany B. A.</creatorcontrib><creatorcontrib>Guimaraes, Danielle A.</creatorcontrib><creatorcontrib>Rizzi, Elen</creatorcontrib><creatorcontrib>Ceron, Carla S.</creatorcontrib><creatorcontrib>Gerlach, Raquel F.</creatorcontrib><creatorcontrib>Tanus‐Santos, Jose E.</creatorcontrib><title>The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension</title><title>Basic &amp; clinical pharmacology &amp; toxicology</title><addtitle>Basic Clin Pharmacol Toxicol</addtitle><description>Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip (2K1C) hypertension‐induced left ventricular remodelling. Sham‐operated controls or 2K1C rats with hypertension received either vehicle or PDTC (100 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure was monitored every week. Histological assessment of left ventricles was carried out with haematoxylin/eosin sections, and fibrosis was quantified in picrosirius red‐stained sections. Oxidative stress was evaluated in heart samples with the dihydroethidium probe. Cardiac MMP activity was determined by in situ zymography, and cardiac MMP‐2 was assessed by immunofluorescence. 2K1C surgery significantly increased systolic blood pressure in the 2K1C vehicle. PDTC exerted antihypertensive effects after 2 weeks of treatment. Histology revealed increased left ventricular and septum wall thickness associated with augmented myocyte diameter in hypertensive rats, which were reversed by treatment with PDTC. Hypertensive rats developed pronounced cardiac fibrosis with increased interstitial collagen area, increased cardiac reactive oxygen species levels, gelatinase activity and MMP‐2 expression. PDTC treatment decreased these alterations. These findings show that PDTC modulates myocardial MMP‐2 expression and ameliorates cardiac remodelling in renovascular hypertension. These results suggest that interfering with MMP expression at transcriptional level may be an interesting strategy in the therapy of organ damage associated with hypertension.</description><subject>Animals</subject><subject>Blood Pressure</subject><subject>Collagen - metabolism</subject><subject>Disease Models, Animal</subject><subject>Fibrosis</subject><subject>Heart Ventricles - drug effects</subject><subject>Heart Ventricles - enzymology</subject><subject>Heart Ventricles - pathology</subject><subject>Heart Ventricles - physiopathology</subject><subject>Hypertension, Renovascular - complications</subject><subject>Hypertension, Renovascular - drug therapy</subject><subject>Hypertension, Renovascular - enzymology</subject><subject>Hypertension, Renovascular - pathology</subject><subject>Hypertension, Renovascular - physiopathology</subject><subject>Hypertrophy, Left Ventricular - enzymology</subject><subject>Hypertrophy, Left Ventricular - etiology</subject><subject>Hypertrophy, Left Ventricular - pathology</subject><subject>Hypertrophy, Left Ventricular - physiopathology</subject><subject>Hypertrophy, Left Ventricular - prevention &amp; control</subject><subject>Male</subject><subject>Matrix Metalloproteinase 2 - metabolism</subject><subject>NF-kappa B - antagonists &amp; inhibitors</subject><subject>NF-kappa B - metabolism</subject><subject>Oxidative Stress - drug effects</subject><subject>Pyrrolidines - pharmacology</subject><subject>Rats, Wistar</subject><subject>Thiocarbamates - pharmacology</subject><subject>Time Factors</subject><subject>Up-Regulation</subject><subject>Ventricular Function, Left - drug effects</subject><subject>Ventricular Remodeling - drug effects</subject><issn>1742-7835</issn><issn>1742-7843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNo9Uc1OGzEQtioqAimXPkBliXPAP7vezbGEApGSNkLhvJpdTxJTx956vZTceIQ-Rx-LJ6kDlLnM6Jtvfj9CPnN2xpOd100bz7jIGPtAjniRiVFRZvLgPZb5gBx33T1josg4OyQDkZdcFTw_In-XG6Tf-8YiBHoFTfSB_oS2hQs6dRtTmz2w2IXgrdHGIb00cWN8A6GGLUSki4AP6GJHJxC0gYbe4tZrtNa4NQWn6RxiMI90jhGs9W3wEY2DDp-f_gh61yZ3i-veQjTeUeNSvfMP0DUJCvRm12KI6LqU_EQ-rsB2ePLmh-Tu6ttycjOa_bieTr7ORq3MORvlWmEueFE2oNV4rEoFIBQohuliyXPguhRS8BJ0ISWOtShXdVY3qDWuADM5JKevfdOuv3rsYnXv--DSyIoXbJwppYRMrC9vrL7eoq7aYLYQdtX_1yYCfyX8NhZ373nOqr1o1V606kW06mKyWL5E8h8MCo-2</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Cau, Stefany B. A.</creator><creator>Guimaraes, Danielle A.</creator><creator>Rizzi, Elen</creator><creator>Ceron, Carla S.</creator><creator>Gerlach, Raquel F.</creator><creator>Tanus‐Santos, Jose E.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201510</creationdate><title>The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension</title><author>Cau, Stefany B. A. ; Guimaraes, Danielle A. ; Rizzi, Elen ; Ceron, Carla S. ; Gerlach, Raquel F. ; Tanus‐Santos, Jose E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p3510-5d6e52178cad699686aa26a60e671315a1d823218ad733e9d28fb4bceddefae43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Blood Pressure</topic><topic>Collagen - metabolism</topic><topic>Disease Models, Animal</topic><topic>Fibrosis</topic><topic>Heart Ventricles - drug effects</topic><topic>Heart Ventricles - enzymology</topic><topic>Heart Ventricles - pathology</topic><topic>Heart Ventricles - physiopathology</topic><topic>Hypertension, Renovascular - complications</topic><topic>Hypertension, Renovascular - drug therapy</topic><topic>Hypertension, Renovascular - enzymology</topic><topic>Hypertension, Renovascular - pathology</topic><topic>Hypertension, Renovascular - physiopathology</topic><topic>Hypertrophy, Left Ventricular - enzymology</topic><topic>Hypertrophy, Left Ventricular - etiology</topic><topic>Hypertrophy, Left Ventricular - pathology</topic><topic>Hypertrophy, Left Ventricular - physiopathology</topic><topic>Hypertrophy, Left Ventricular - prevention &amp; control</topic><topic>Male</topic><topic>Matrix Metalloproteinase 2 - metabolism</topic><topic>NF-kappa B - antagonists &amp; inhibitors</topic><topic>NF-kappa B - metabolism</topic><topic>Oxidative Stress - drug effects</topic><topic>Pyrrolidines - pharmacology</topic><topic>Rats, Wistar</topic><topic>Thiocarbamates - pharmacology</topic><topic>Time Factors</topic><topic>Up-Regulation</topic><topic>Ventricular Function, Left - drug effects</topic><topic>Ventricular Remodeling - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cau, Stefany B. A.</creatorcontrib><creatorcontrib>Guimaraes, Danielle A.</creatorcontrib><creatorcontrib>Rizzi, Elen</creatorcontrib><creatorcontrib>Ceron, Carla S.</creatorcontrib><creatorcontrib>Gerlach, Raquel F.</creatorcontrib><creatorcontrib>Tanus‐Santos, Jose E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Basic &amp; clinical pharmacology &amp; toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cau, Stefany B. A.</au><au>Guimaraes, Danielle A.</au><au>Rizzi, Elen</au><au>Ceron, Carla S.</au><au>Gerlach, Raquel F.</au><au>Tanus‐Santos, Jose E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension</atitle><jtitle>Basic &amp; clinical pharmacology &amp; toxicology</jtitle><addtitle>Basic Clin Pharmacol Toxicol</addtitle><date>2015-10</date><risdate>2015</risdate><volume>117</volume><issue>4</issue><spage>234</spage><epage>241</epage><pages>234-241</pages><issn>1742-7835</issn><eissn>1742-7843</eissn><abstract>Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip (2K1C) hypertension‐induced left ventricular remodelling. Sham‐operated controls or 2K1C rats with hypertension received either vehicle or PDTC (100 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure was monitored every week. Histological assessment of left ventricles was carried out with haematoxylin/eosin sections, and fibrosis was quantified in picrosirius red‐stained sections. Oxidative stress was evaluated in heart samples with the dihydroethidium probe. Cardiac MMP activity was determined by in situ zymography, and cardiac MMP‐2 was assessed by immunofluorescence. 2K1C surgery significantly increased systolic blood pressure in the 2K1C vehicle. PDTC exerted antihypertensive effects after 2 weeks of treatment. Histology revealed increased left ventricular and septum wall thickness associated with augmented myocyte diameter in hypertensive rats, which were reversed by treatment with PDTC. Hypertensive rats developed pronounced cardiac fibrosis with increased interstitial collagen area, increased cardiac reactive oxygen species levels, gelatinase activity and MMP‐2 expression. PDTC treatment decreased these alterations. These findings show that PDTC modulates myocardial MMP‐2 expression and ameliorates cardiac remodelling in renovascular hypertension. These results suggest that interfering with MMP expression at transcriptional level may be an interesting strategy in the therapy of organ damage associated with hypertension.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>25816715</pmid><doi>10.1111/bcpt.12400</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1742-7835
ispartof Basic & clinical pharmacology & toxicology, 2015-10, Vol.117 (4), p.234-241
issn 1742-7835
1742-7843
language eng
recordid cdi_proquest_journals_1709466623
source Wiley
subjects Animals
Blood Pressure
Collagen - metabolism
Disease Models, Animal
Fibrosis
Heart Ventricles - drug effects
Heart Ventricles - enzymology
Heart Ventricles - pathology
Heart Ventricles - physiopathology
Hypertension, Renovascular - complications
Hypertension, Renovascular - drug therapy
Hypertension, Renovascular - enzymology
Hypertension, Renovascular - pathology
Hypertension, Renovascular - physiopathology
Hypertrophy, Left Ventricular - enzymology
Hypertrophy, Left Ventricular - etiology
Hypertrophy, Left Ventricular - pathology
Hypertrophy, Left Ventricular - physiopathology
Hypertrophy, Left Ventricular - prevention & control
Male
Matrix Metalloproteinase 2 - metabolism
NF-kappa B - antagonists & inhibitors
NF-kappa B - metabolism
Oxidative Stress - drug effects
Pyrrolidines - pharmacology
Rats, Wistar
Thiocarbamates - pharmacology
Time Factors
Up-Regulation
Ventricular Function, Left - drug effects
Ventricular Remodeling - drug effects
title The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T05%3A30%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Nuclear%20Factor%20kappaB%20Inhibitor%20Pyrrolidine%20Dithiocarbamate%20Prevents%20Cardiac%20Remodelling%20and%20Matrix%20Metalloproteinase%E2%80%902%20Up%E2%80%90Regulation%20in%20Renovascular%20Hypertension&rft.jtitle=Basic%20&%20clinical%20pharmacology%20&%20toxicology&rft.au=Cau,%20Stefany%20B.%20A.&rft.date=2015-10&rft.volume=117&rft.issue=4&rft.spage=234&rft.epage=241&rft.pages=234-241&rft.issn=1742-7835&rft.eissn=1742-7843&rft_id=info:doi/10.1111/bcpt.12400&rft_dat=%3Cproquest_pubme%3E3797558641%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p3510-5d6e52178cad699686aa26a60e671315a1d823218ad733e9d28fb4bceddefae43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1709466623&rft_id=info:pmid/25816715&rfr_iscdi=true